Photo from Neil Iyengar/Twitter
Sep 28, 2023, 18:04
Neil Iyengar: We found Hb A1c and BMI were early risk factors for treatment discontinuation.
Quoting Neil Iyengar, Associate Professor at Memorial Sloan Kettering Cancer Center, on X/Twitter:
”New study: Early PIK3CA and Hemoglobin A1c testing is critical to provide time to improve glycemic status before starting alpelisib for metastatic breast cancer. We found Hb A1c and BMI were early risk factors for treatment discontinuation.”
For the article click here.
Source: Neil Iyengar/Twitter
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 8, 2025, 21:29
Aug 8, 2025, 21:08
Aug 8, 2025, 20:54
Aug 8, 2025, 20:18
Aug 8, 2025, 20:03
Aug 8, 2025, 19:51
Aug 8, 2025, 19:34